Nuo Therapeutics CEO awarded 13,245 AURX shares

Nuo Therapeutics, Inc. director and CEO/CFO David Emerson Jorden reported acquiring 13,245 shares of Common Stock in a grant or award transaction at a weighted average price of $1.0952 per share.

Rhea-AI Filing Summary

Nuo Therapeutics, Inc. director and CEO/CFO David Emerson Jorden reported acquiring 13,245 shares of Common Stock in a grant or award transaction at a weighted average price of $1.0952 per share. Following this award, he directly holds 2,085,000 shares. A footnote explains the reported price is a weighted average based on multiple transactions with individual share prices ranging from $1.042 to $1.15.

Insider Trade Summary

Grant/Award: 13,245 shares

Grant/Award 1 txn

Insider JORDEN DAVID EMERSON

Role CEO/CFO

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	13,245	$1.0952	$15K

Holdings After Transaction: Common Stock — 2,085,000 shares (Direct)

Footnotes (1)

1. F1. The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.042 to $1.15, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate transaction with the range set forth herein.

Key Figures

Shares acquired: 13,245 shares Weighted average price: $1.0952 per share Post-transaction holdings: 2,085,000 shares +2 more

5 metrics

Shares acquired 13,245 shares Common Stock grant/award acquisition

Weighted average price $1.0952 per share Reported transaction price for acquired shares

Post-transaction holdings 2,085,000 shares Total Common Stock directly held after transaction

Low price range $1.042 per share Lowest individual price in multiple transactions

High price range $1.15 per share Highest individual price in multiple transactions

Key Terms

weighted average price, Grant, award, or other acquisition, Common Stock, non-derivative

4 terms

weighted average price financial

"The price reported in Column 4 is a weighted average price."

Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.

Grant, award, or other acquisition financial

"transaction_code_description": "Grant, award, or other acquisition""

Common Stock financial

""security_title": "Common Stock""

Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.

non-derivative financial

""transaction_type": "non-derivative""

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Nuo Therapeutics (AURX) report for David Emerson Jorden?

Nuo Therapeutics reported that CEO/CFO David Emerson Jorden acquired 13,245 shares of Common Stock as a grant or award. This non-derivative acquisition increased his direct holdings to 2,085,000 shares, according to the Form 4 insider filing.

At what price were the new Nuo Therapeutics (AURX) shares reported for David Jorden?

The filing shows a weighted average price of $1.0952 per share for the 13,245 acquired shares. A footnote states these were purchased in multiple transactions at prices ranging from $1.042 to $1.15 per share.

How many Nuo Therapeutics (AURX) shares does David Emerson Jorden hold after this Form 4?

After this reported acquisition, David Emerson Jorden directly holds 2,085,000 shares of Nuo Therapeutics Common Stock. This total reflects the additional 13,245 shares received in the grant or award transaction disclosed in the Form 4.

What transaction code was used in the Nuo Therapeutics (AURX) Form 4 for David Jorden?

The Form 4 lists transaction code “A,” which denotes a grant, award, or other acquisition. The transaction is classified as non-derivative Common Stock, indicating an equity award rather than a derivative exercise or open-market sale.

Was the Nuo Therapeutics (AURX) insider transaction an acquisition or a sale?

The insider transaction is classified as an acquisition. Form 4 data shows transaction direction “acquire” with an action type of grant or award, and there are no corresponding sale or disposition entries reported for this filing.

Does David Emerson Jorden hold Nuo Therapeutics (AURX) shares directly or indirectly?

The filing indicates that David Emerson Jorden’s ownership of Nuo Therapeutics shares is direct. The ownership code is listed as “D,” and there is no nature-of-ownership footnote describing indirect entities such as trusts or LLCs.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/05/2026 - 06:34 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

JORDEN DAVID EMERSON

(Last) (First) (Middle)

C/O NUO THERAPEUTICS, INC.

8285 EL RIO, SUITE190

(Street)

HOUSTON TEXAS 77054

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Nuo Therapeutics, Inc. [ AURX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	CEO/CFO

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/05/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	06/05/2026		A		13,245	A	$1.0952(1)	2,085,000	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.042 to $1.15, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate transaction with the range set forth herein.

	/s/ David Jorden	06/05/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)